Business Context and Reporting Period
This Form 8-K was filed by Bionano Genomics, Inc. on May 14, 2020. The filing primarily addresses a delay in the submission of the Quarterly Report on Form 10-Q for the period ended March 31, 2020, and provides a risk factor update regarding the impact of the COVID-19 pandemic. The Company is an emerging growth company incorporated in Delaware.
Financial Metrics and Liquidity
The filing references a press release (Exhibit 99.1) containing preliminary financial information for the three months ended March 31, 2020, but does not explicitly state specific revenue, profit, cash flow, or margin figures within the text of this 8-K. The Company notes it is subject to affirmative and negative covenants in its loan agreement and warns that economic downturns may limit its ability to access capital, potentially affecting liquidity.
Material Changes and Operational Disruptions
The Company reports significant disruptions to its operations and business due to the COVID-19 pandemic, including:
- Implementation of work-from-home policies and temporary scaling back of operations.
- Disruptions to global commercialization efforts and supply chains, particularly affecting distributors in China (5% of 2019 revenue) and the Asia Pacific region (14% of 2019 revenue).
- Reduced productivity due to remote work limitations and employee access issues to closed offices.
- Delays in customer payments and potential defaults on purchase orders for consumables and Saphyr instruments.
Guidance, Outlook, and Risks
Guidance Suspension: The Company has suspended all guidance, projections, and outlook for 2020, including previous forward-looking statements regarding gross margin improvements and sales growth.
Filing Delay: The Form 10-Q for the quarter ended March 31, 2020, is delayed due to the time required for finance and accounting teams to address pandemic-related operational issues. The Company expects to file the report on or prior to June 18, 2020.
Key Risks:
- Loan Covenants: Potential default on loan agreements if financial covenants are breached, which could lead to accelerated repayment obligations or loss of pledged assets.
- Supply Chain: Anticipated shortages in materials required to operate instruments, limiting the ability to process customer samples.
- Market Access: Restrictions on travel and stay-at-home orders have limited the ability to provide installation, training, and customer service.
Key Facts for Investor Verification
- Verify the specific preliminary financial results for Q1 2020 in the attached press release (Exhibit 99.1), as this 8-K does not contain the numerical data.
- Monitor the status of the delayed Form 10-Q filing, expected by June 18, 2020.
- Assess the Company's compliance with loan covenants given the potential for revenue delays and increased costs.
- Review the extent of supply chain disruptions, specifically regarding materials for instrument operation and distributor stability in China.
- Confirm the timeline for resuming normal commercialization activities and customer support services.